Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B

Details for Australian Patent Application No. 2004269897 (hide)

International Classifications

Event Publications

27 April 2006 PCT application entered the National Phase

PCT publication WO2005/023318 Priority application(s): WO2005/023318

30 July 2009 Alteration of Name

The name of the applicant has been altered to Philogen S.p.A.; Bayer Schering Pharma Aktiengesellschaft

5 November 2009 Application Accepted

Published as AU-B-2004269897

4 March 2010 Standard Patent Sealed

8 March 2012 Assignment Registered

Bayer Schering Pharma Aktiengesellschaft; Philogen S.p.A. The patent has been assigned to Philogen S.p.A

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.